ORAI3 and prostate carcinoma: First, application of 2-APB, which blocks currents via Orai1 and enhances currents via Orai3 [75], resulted in stronger amplification of ICRAC in primary human prostate epithelial cells (hPECs) from healthy tissue compared to prostate cancer cells [29].